| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 May 2026 | 22 Apr 2026 |
| Glaxosmithkline Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2026 inter alia to consider and approve Audited Financial Results (Standalone & Consolidated) for the year ended 31st March 2026 and dividend if any Outcome of Meeting (As per BSE Announcement dated on: 13.05.2026) | ||
| Board Meeting | 2 Mar 2026 | 2 Mar 2026 |
| Outcome Of Board Meeting | ||
| Board Meeting | 9 Feb 2026 | 6 Jan 2026 |
| Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve take on record the Un-audited financial results for the third quarter & nine months ended 31st December 2025. Outcome of Meeting (As Per BSE Announcement Dated on: 09/02/2026) | ||
| Board Meeting | 6 Nov 2025 | 27 Oct 2025 |
| Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve Approval of Un-audited financial results for the quarter & half year ended 30th September 2025. Outcome of meeting (As Per Bse Announcement dated on 06/11/2025) | ||
| Board Meeting | 1 Aug 2025 | 26 Jun 2025 |
| As per attachment We wish to inform you that the in terms of the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading period for buying or selling of Companys shares is closed from Tuesday, 1st July 2025 and shall reopen on Wednesday, 6th August 2025 i.e. after the approval & declaration of Un-Audited financial results for first quarter ended 30th June 2025 by the Board of Directors at its meeting scheduled to be held on Friday, 1st August 2025. Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2025 ,inter alia, to consider and approve Board Meeting Intimation (As Per BSE Announcement Dated on :04.07.2025) As per attachment (As Per BSE Announcement Dated on: 01.08.2025) | ||
At around 2.14 PM, GSK Pharma was trading 0.28% higher at ₹2,806.70 per piece, against the previous close of ₹2,798.80 on NSE.
Here are some of the stocks that may see significant price movement today: GIC Re, GSK Pharma, Godfrey Philips, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
